Provided by Tiger Trade Technology Pte. Ltd.

Syndax Pharmaceuticals

21.19
+0.18000.86%
Post-market: 21.190.00000.00%19:59 EST
Volume:1.09M
Turnover:22.91M
Market Cap:1.84B
PE:-5.89
High:21.35
Open:20.92
Low:20.75
Close:21.01
52wk High:22.73
52wk Low:8.58
Shares:86.91M
Float Shares:72.72M
Volume Ratio:0.86
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6004
EPS(LYR):-3.7228
ROE:-129.32%
ROA:-39.24%
PB:15.96
PE(LYR):-5.69

Loading ...

Syndax Pharmaceuticals nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

Reuters
·
Feb 05

BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 05

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 05

Assessing Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Momentum And Mixed Performance

Simply Wall St.
·
Feb 05

Syndax Pharmaceuticals (SNDX) Receives a Buy from Barclays

TIPRANKS
·
Feb 04

Syndax price target raised to $28 from $27 at BofA

TIPRANKS
·
Feb 03

Syndax Pharmaceuticals Is Maintained at Outperform by Mizuho

Dow Jones
·
Jan 28

Stock Track | Syndax Pharmaceuticals Plummets 5.20% Intraday Amid Conflicting Analyst Sentiments

Stock Track
·
Jan 13

Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating

TIPRANKS
·
Jan 13

Syndax Pharmaceuticals to Present Business Updates at J.P. Morgan Healthcare Conference

Reuters
·
Jan 12

Syndax Pharmaceuticals Reports Strong 2025 Revenue Growth and Cash Position

Reuters
·
Jan 12

Syndax Pharmaceuticals : Ended 2025 With About$394 Million in Cash, Cash Equivalents and Marketable Securities

THOMSON REUTERS
·
Jan 12

Syndax Pharmaceuticals Inc - Revuforj Net Revenue up 38% in Q4 2025 VS Q3 2025

THOMSON REUTERS
·
Jan 12

Press Release: Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Dow Jones
·
Jan 12

Syndax Pharmaceuticals Inc - Co and Woda to Expand Access to Revuforj Outside U.S.

THOMSON REUTERS
·
Jan 07

Syndax: Program Will Be Launched in Parts of Eurasia, Central and Southeast Europe, Israel, Middle East and Turkey, Latin America, and Africa

THOMSON REUTERS
·
Jan 07

Syndax Pharmaceuticals and WODA Launch Global Access Program for Revuforj

Reuters
·
Jan 07

Syndax Announces Presentation at the 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 05

Syndax Pharmaceuticals Moves to Uncertificated Shares

Reuters
·
Dec 20, 2025

Syndax Pharmaceuticals Price Target Maintained With a $56.00/Share by BTIG

Dow Jones
·
Dec 09, 2025